Table 1 Characteristics of trials and outcomes for Center 1 and Center 2 sets
Characteristics | Center 1 Set (N = 303) | Center 2 Set (N = 227) | P Chi2 | ||
|---|---|---|---|---|---|
N (%) | Median (Min-Max) | N (%) | Median (Min-Max) | ||
Number of trials | 51 | 40 | |||
Patients by trials | 4 (1–31) | 2 (1–22) | |||
Trial randomization | 0.13 | ||||
Yes | 30 (59) | 25 (63) | |||
No | 21 (41) | 15 (37) | |||
Trial promotion | 0.08 | ||||
Academic | 25 (49) | 27 (68) | |||
Industrial | 26 (51) | 13 (32) | |||
Protocol defined treatments | <0.001 | ||||
Chemotherapy-based regimen | 154 (51) | 157 (69) | |||
Targeted therapies only (targeted therapies and/or endocrine therapy) | 149 (49) | 70 (31) | |||
Protocol specified “life expectancy” criterion (per patient) | 0.003 | ||||
Yes | 73 (24) | 82 (36) | |||
No | 230 (76) | 145 (64) | |||
Treatment duration (months) | 4 (0–44) | 4 (0–49) | |||
Reason for discontinuing trial | <0.001 | ||||
Progression | 198 (65) | 136 (60) | |||
Programmed end of the trial | 42 (14) | 6 (3) | |||
Toxicity | 32 (10) | 37 (16) | |||
Death | 12 (4) | 2 (1) | |||
Patient Retrial | 8 (3) | 9 (4) | |||
Other | 8 (3) | 18 (8) | |||
NA | 3 (1) | 19 (8) | |||
Median follow-up (months) | 17 (0–77) | 12 (0–50) | |||
Three-month mortality rate | 37 (12) | 20 (9) | |||
Six-month mortality rate | 59 (20) | 41 (18) | |||